---
aliases: [NTRA]
---
#actor #genomics #diagnostics #prenatal #oncology #usa #public

**Natera** — Genetic testing leader. Panorama NIPT. Signatera MRD. ~$2.2B revenue, 35% growth.

---

## Why Natera matters

| Metric | Value |
|--------|-------|
| Ticker | NTRA |
| Market cap | ~$18B |
| 2025E revenue | **$2.18-2.26B** |
| TTM revenue | $2.12B |
| Growth | **35%** (Q3 2025) |

---

## 2025 financial performance

| Quarter | Revenue | YoY growth |
|---------|---------|------------|
| Q1 2025 | $502M | +37% |
| Q2 2025 | ~$530M | +30%+ |
| Q3 2025 | ~$570M | +35% |

**Guidance raised multiple times** throughout 2025.

---

## Business segments

### Women's Health

| Product | Application | Position |
|---------|-------------|----------|
| **Panorama** | NIPT (prenatal screening) | Market leader |
| **Fetal Focus** | Single-gene NIPT | New launch |
| Horizon | Carrier screening | Growing |

### Oncology

| Product | Application | Position |
|---------|-------------|----------|
| **Signatera** | MRD monitoring | **Category leader** |
| Altera | Tumor profiling | Companion |

### Organ Health

| Product | Application |
|---------|-------------|
| Prospera | Transplant rejection monitoring |

---

## Signatera MRD

**Personalized cancer monitoring test**

| Feature | Detail |
|---------|--------|
| Method | Custom assay from tumor DNA |
| Sensitivity | Detects recurrence 16+ months early |
| ASP | ~$1,175 |
| Volume growth | **+54%** (Q3 2025) |
| Medicare coverage | Multiple cancers |
| Clinical trials | 100+ ongoing |

### Covered indications

- Colorectal cancer (stage II-III)
- Breast cancer
- Muscle-invasive bladder cancer
- Expanding to additional tumor types

---

## Panorama NIPT

| Feature | Detail |
|---------|--------|
| Market position | #1 NIPT provider |
| Technology | SNP-based (proprietary) |
| Applications | Chromosomal abnormalities, twins |
| New: Fetal Focus | Single-gene testing (maternal only) |

---

## Competitive landscape

| Segment | Competitors |
|---------|-------------|
| NIPT | [[Illumina]], Myriad, Labcorp |
| MRD | Guardant (Reveal), Foundation, Tempus |
| Transplant | CareDx |

**Signatera advantage:** Personalized approach, Medicare coverage, clinical validation.

---

## Investment case

**Bull:**
- Signatera MRD category leader
- 54% oncology volume growth
- Medicare coverage expanding
- Panorama market leadership
- 100+ clinical trials = pipeline
- Raised guidance multiple times

**Bear:**
- Still unprofitable
- Reimbursement risk (new indications)
- Competition from Guardant, Foundation
- High growth expectations priced in
- Clinical adoption takes time

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | NTRA |
| 2025E revenue | ~$2.2B |
| Key products | Signatera, Panorama |
| Growth | 35% |

---

## Related

- [[Guardant Health]] — competitor (oncology)
- [[Exact Sciences]] — competitor (cancer)
- [[Illumina]] — competitor (NIPT)
- [[Genomics]] — sector concept
- [[Tempus]] — competitor (oncology)

---

## Sources

- [Natera Q3 2025](https://www.investing.com/news/company-news/natera-q3-2025-slides-revenue-soars-35-guidance-raised-despite-eps-miss-93CH-4340896)
- [GenomeWeb Coverage](https://www.genomeweb.com/business-news/natera-raises-full-year-revenue-guidance-test-volume-growth-rosy-reimbursement)

*Created 2026-01-09*
